1. Dongiovanni, Paola, Meroni, Marica, Baselli, Guido, Kozlitina, Julia, Valenti, Luca. 2019. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. In Journal of lipid research, 60, 1144-1153. doi:10.1194/jlr.P090449. https://pubmed.ncbi.nlm.nih.gov/30918065/
2. Carr, Rotonya M, Davidson, Nicholas O. 2019. Building bridges: PCSK7 as a NAFLD candidate gene connecting hepatic inflammation with hypertriglyceridemia. In Journal of lipid research, 60, 1067-1068. doi:10.1194/jlr.C094888. https://pubmed.ncbi.nlm.nih.gov/31023721/
3. Vargas-Alarcón, Gilberto, Pérez-Méndez, Oscar, González-Pacheco, Héctor, Escobedo, Galileo, Fragoso, José Manuel. 2021. The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin-Kexin Type 7 (PCSK7) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides. In Cells, 10, . doi:10.3390/cells10061444. https://pubmed.ncbi.nlm.nih.gov/34207761/
4. Buch, Stephan, Sharma, Aneesh, Ryan, Eleanor, Stickel, Felix, Morgan, Marsha Y. 2021. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis. In Alimentary pharmacology & therapeutics, 53, 830-843. doi:10.1111/apt.16252. https://pubmed.ncbi.nlm.nih.gov/33565643/
5. Huang, Tao, Huang, Jinyan, Qi, Qibin, Sacks, Frank M, Qi, Lu. 2014. PCSK7 genotype modifies effect of a weight-loss diet on 2-year changes of insulin resistance: the POUNDS LOST trial. In Diabetes care, 38, 439-44. doi:10.2337/dc14-0473. https://pubmed.ncbi.nlm.nih.gov/25504030/
6. Malakootian, Mahshid, Naeli, Parisa, Mowla, Seyed Javad, Seidah, Nabil G. 2022. Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators. In Metabolites, 12, . doi:10.3390/metabo12070588. https://pubmed.ncbi.nlm.nih.gov/35888711/
智鼠故事 
